Evercore ISI Group Initiates Coverage On Moderna with In-Line Rating, Announces Price Target of $120
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has initiated coverage on Moderna (MRNA) with an In-Line rating and set a price target of $120. This new coverage was announced by analyst Cory Kasimov.

May 14, 2024 | 9:14 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Evercore ISI Group's initiation of coverage on Moderna with an In-Line rating and a price target of $120 could influence investor sentiment and potentially stabilize the stock's price around the target in the short term.
Analyst ratings and price targets often influence investor sentiment and stock prices in the short term. An In-Line rating suggests that Evercore ISI Group views Moderna's stock as fairly valued at its current price, implying a neutral short-term impact. The announcement of a specific price target provides a benchmark for investors, potentially stabilizing the stock's price if it aligns with market expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100